The first experience of using synthetic Antithrombin-III (Athenativ) in cardiosurgical practice
Abstract
Nowadays, the main share of heart surgery performed under artificial circulation, accompanied by a violation of hemostasis. Deficit antithrombin III is 0.02–1% of the population. The main clinical manifestation of deficiency of antithrombin III is thrombosis. The work conducted its own study of communication between levels of antithrombin-III and the result of the activated clotting time during cardiopulmonary bypass in cardiac practice.
Demonstrated that the quantitative and/or qualitative deficiency of antithrombin-III results in early postoperative complications and disorders in the hemostatic system.
During 2016 at the GI «Scientific-Practical Children`s Cardiac Center» an analysis of 11 patients, average age amounted to 50,2±27,2 years. In 5 (45.4%) patients were available concomitant diseases, in 4 (36.4%) patients – infective endocarditis, in 1 (9%) – HCV. The level of antithrombin-III in the study group amounted to 87.5% in patients with existing co-morbidities – 110.4%, indicating a qualitative deficiency of antithrombin-III in patients with concomitant infectious disease. Averages activated coaghulation time in patients formed the study group 352,4±18,6 seconds after the introduction of additional synthetic antithrombin-III under artificial circulation it reached 535±77 s.
We recommend using empirical synthetic antithrombin-III cardiac patients with AСT less than 400 seconds for the exclusion of intraoperative complications such as thrombosis.
References
2. Bical O. M. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery / O. M. Bical, Y. Fromes, D. Gaillard et al. // Eur. J. Cardiothorac. Surg. – 2006. – Vol. 29, № 5. – P. 699–702.
3. Burkhart C. S. Modifiable and nonmodifiable risk factors for postoperative delirium after cardiac surgery with cardiopulmonary bypass / C. S. Burkhart, S. Dell-Kuster, M. Gamberini et al. // J. Thorac. Cardiovasc. Surg. – 2010. – Vol. 24. – P. 555–559.
4. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis / Diaz R., Moffett B. S., Karabinas S. et al. // J Pediatr. – 2015. – Vol. 167. – P. 645–649.
5. Finley Alan, Greenberg Charles. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass // Anesthesia and analgesia. – 2013-06-01. – Vol. 6. – P. 1210–1222.
6. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis / Gando S., Saitoh D., Ishikura H. et al. // Critical Care. – 2013. – Vol. 1. – R297.
7. Guidelines for antithrombin use at ucdmc. 6/2015.
8. Edward F. Goljan (2011). Pathology. Mosby/Elsevier. Retrieved 24 August 2014. – P. 251.
9. Peripheral nerve injuries during cardiac surgery: risk factors, diagnosis, prognosis, and prevention / Sharma A. D., Parmley C. L., Sreeram G. et al. // J Thorac Cardiovasc Surg. – 1991. – Vol. 102. – P.724–9.
10. Knapik P., Cies 2la D. Incidence and prediction of permanent neurological deficits after cardiac surgery – are the existing models of prediction truly global? // Eur J Cardiothorac Surg. – 2010. – Vol. 37. – P. 717–723.
11. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates // Blood Transfus. – 2009 Oct. – Vol. 7 (4). – P. 325–334.
